Namwiwat Medical Corporation PCL (BKK:NAM)
Thailand · Delayed Price · Currency is THB 3.300
+0.020 (0.61%)
Last updated: Sep 8, 2026, 2:17 PM ICT
BKK:NAM Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,688 | 1,870 | 1,114 | 1,101 | 1,099 | 995.36 |
Other Revenue | - | - | - | - | 0.99 | - |
| 1,688 | 1,870 | 1,114 | 1,101 | 1,100 | 995.36 | |
Revenue Growth | 4.61% | 67.79% | 1.24% | 0.04% | 10.55% | 46.63% |
Cost of Revenue | 1,177 | 1,329 | 646.51 | 620.7 | 772.91 | 654.73 |
Gross Profit | 511.72 | 540.57 | 467.87 | 480.05 | 327.45 | 340.63 |
Selling, General & Admin | 404.16 | 384.68 | 255.54 | 230.16 | 103.39 | 115.18 |
Operating Expenses | 404.16 | 384.68 | 255.54 | 230.16 | 103.39 | 115.18 |
Operating Income | 107.55 | 155.9 | 212.33 | 249.9 | 224.06 | 225.45 |
Interest Expense | -18.11 | -23.33 | -12.68 | -15.73 | -12.99 | -14.03 |
Interest & Investment Income | 7.29 | 8.98 | 15.64 | 1.57 | 1.06 | 0.02 |
Earnings From Equity Investments | - | - | - | - | -0.55 | -0.27 |
Currency Exchange Gain (Loss) | 1.71 | 1.71 | 9.46 | - | 13.04 | 1.14 |
Other Non Operating Income (Expenses) | 9.29 | 5.12 | 5.1 | 1.65 | -8.14 | - |
EBT Excluding Unusual Items | 107.74 | 148.38 | 229.84 | 237.39 | 216.48 | 212.3 |
Gain (Loss) on Sale of Investments | 0.23 | 0.8 | 1.96 | 2.32 | - | - |
Gain (Loss) on Sale of Assets | 1.14 | 0.01 | 0.14 | 10.57 | 5.44 | 1.48 |
Pretax Income | 109.1 | 149.18 | 231.94 | 250.28 | 221.91 | 213.78 |
Income Tax Expense | 23.32 | 27.75 | 49.12 | 49.53 | 46.2 | 44.1 |
Earnings From Continuing Operations | 85.78 | 121.43 | 182.83 | 200.75 | 175.71 | 169.68 |
Minority Interest in Earnings | -4.46 | -19.84 | -1.96 | - | - | 4.97 |
Net Income | 81.33 | 101.59 | 180.87 | 200.75 | 175.71 | 174.65 |
Net Income to Common | 81.33 | 101.59 | 180.87 | 200.75 | 175.71 | 174.65 |
Net Income Growth | -54.82% | -43.83% | -9.90% | 14.25% | 0.61% | 56.17% |
Shares Outstanding (Basic) | 700 | 700 | 700 | 615 | 26 | 20 |
Shares Outstanding (Diluted) | 700 | 700 | 700 | 615 | 26 | 20 |
Shares Change | - | - | 13.90% | 2237.63% | 31.45% | - |
EPS (Basic) | 0.12 | 0.15 | 0.26 | 0.33 | 6.68 | 8.73 |
EPS (Diluted) | 0.12 | 0.15 | 0.26 | 0.33 | 6.68 | 8.73 |
EPS Growth | -54.82% | -43.83% | -20.90% | -95.11% | -23.46% | 56.17% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 37.74 | -4.94 | -32.64 | 228.27 | -81.16 | 93.61 |
Free Cash Flow Per Share | 0.05 | -0.01 | -0.05 | 0.37 | -3.09 | 4.68 |
Dividend Per Share | 0.130 | 0.130 | 0.150 | 0.090 | - | - |
Dividend Growth | -13.33% | -13.33% | 66.67% | - | - | - |
Gross Margin | 30.31% | 28.91% | 41.98% | 43.61% | 29.76% | 34.22% |
Operating Margin | 6.37% | 8.34% | 19.05% | 22.70% | 20.36% | 22.65% |
Profit Margin | 4.82% | 5.43% | 16.23% | 18.24% | 15.97% | 17.55% |
Free Cash Flow Margin | 2.23% | -0.26% | -2.93% | 20.74% | -7.38% | 9.40% |
EBITDA | 164.57 | 212.28 | 238.27 | 275.13 | 241.25 | 239.88 |
EBITDA Margin | 9.75% | 11.35% | 21.38% | 25.00% | 21.93% | 24.10% |
D&A For EBITDA | 57.02 | 56.38 | 25.94 | 25.23 | 17.19 | 14.43 |
EBIT | 107.55 | 155.9 | 212.33 | 249.9 | 224.06 | 225.45 |
EBIT Margin | 6.37% | 8.34% | 19.05% | 22.70% | 20.36% | 22.65% |
Effective Tax Rate | 21.38% | 18.60% | 21.18% | 19.79% | 20.82% | 20.63% |
Revenue as Reported | 1,701 | 1,877 | 1,131 | 1,115 | 1,111 | 997.98 |